MP69-08 PHARMACEUTICAL INDUSTRY PAYMENTS AND PHYSICIAN PRESCRIBING OF UROLOGIC DRUGS

Physician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs

BACKGROUND The U.S. Physician Payments Sunshine Act mandates the reporting of payments or items of value received by physicians from drug, medical device, and biological agent manufacturers. The impact of these payments on physician prescribing has not been examined at large scale. METHODS We linked public Medicare Part D prescribing data and Sunshine Act data for 2013. Physician payments wer...

Physician education and the pharmaceutical industry.

I n the current issue of CHEST (see pages 1255 and 1257), two thoughtful leaders of the American College of Chest Physicians (ACCP) frame an issue that confronts most physicians today—the relationship between us, the physicians, and the medical products industry. This relationship connects those who sell medical products (pharmaceutical or technology) and those who prescribe the use of those pr...

Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data

BACKGROUND While many new medications may offer advantages over existing drugs, some newer drugs are reformulations of existing products that provide little innovation or incremental benefit while driving up drug costs. Despite the lack of benefit of these medications, prescribers may be motivated by payments made by the pharmaceutical industry. The objective of the study was to determine the a...

US drug marketing: how does promotion correspond with health value?

The pharmaceutical industry uses a variety of techniques to promote its products to clinicians, including gifts and free food, advertisements, and detailing by company representatives. Although manufacturers might argue that drug promotion supports physician education, which in turn leads to more informed prescribing, studies have shown that greater contact with drug sales representatives is as...

Biotechnology and the pharmaceutical industry. New cardiovascular drugs.